The U.S. Food and Drug Administration has approved a device, called RELiZORB®, that helps break down beneficial fats in supplemental nutrition provided via G-tubes.
A $7.5 million research award will go to Southern Research to identify potential new drugs for people with rare CF mutations, known as nonsense mutations, Cystic Fibrosis Foundation Therapeutics Inc. announced today.
The Cystic Fibrosis Foundation has awarded more than $23 million across 11 sites in its Research Development Program (RDP), a network of research centers that brings together top-notch scientists from different disciplines to apply their expertise to the challenges of treating cystic fibrosis.
The Cystic Fibrosis Foundation celebrates the FDA's approval today of the lumacaftor/ivacaftor combination drug (Orkambi™) as an important advance for the cystic fibrosis community. Orkambi targets the underlying cause of the disease in people with two copies of the most common CF gene mutation.
The Cystic Fibrosis Foundation recently hosted the CFF Research Conference: Pushing the Frontiers, bringing together nearly 150 basic scientists, clinical researchers, graduate students and pharmaceutical company representatives to share information on recent advances and critical challenges in CF drug discovery and development.
Cystic Fibrosis Foundation Therapeutics Inc. (CFFT), the nonprofit affiliate of the Cystic Fibrosis Foundation, announced today a $5 million development award to Corbus Pharmaceuticals for a potential new therapy to reduce lung inflammation in people with CF.
Program Aimed at Advancing Search for Therapies Targeting Most Common Mutation of CF
The Associated Press published a story this week highlighting the Cystic Fibrosis Foundation's "groundbreaking" drug development model and its role in developing CF treatments that target the root cause of the disease.